NO20034612D0 - 3,4-di-substituerte syklobuten-1,2-dioner som CXC-kjemokine reseptorligander - Google Patents

3,4-di-substituerte syklobuten-1,2-dioner som CXC-kjemokine reseptorligander

Info

Publication number: NO20034612D0
Authority: NO; Norway
Prior art keywords: dione; chemokine receptor; receptor ligands; cxc chemokine; substituted cyclobutene
Prior art date: 2001-04-16

Application number

NO20034612A

Other languages

English (en)

Other versions

NO20034612L (no

NO330790B1 (no

Inventor

Arthur G Taveras

Cynthia J Aki

Richard W Bond

Jianping Chao

Michael Dwyer

Johan A Ferreira

Jianhua Chao

Younong Yu

John J Baldwin

Bernd Kaiser

Ge Li

J Robert Merritt

Kingsley H Nelson

Laura L Rokosz

Original Assignee

Pharmacopeia Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-04-16

Filing date

2003-10-15

Publication date

2003-10-15

2003-10-15 Application filed by Pharmacopeia Inc filed Critical Pharmacopeia Inc

2003-10-15 Publication of NO20034612D0 publication Critical patent/NO20034612D0/no

2003-12-08 Publication of NO20034612L publication Critical patent/NO20034612L/no

2011-07-18 Publication of NO330790B1 publication Critical patent/NO330790B1/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
- C07C225/20—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of the carbon skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
- C07C237/30—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to hydrogen atoms or to acyclic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
- C07C255/59—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/36—Nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/04—Systems containing only non-condensed rings with a four-membered ring

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Virology (AREA)
Pulmonology (AREA)
Communicable Diseases (AREA)
Immunology (AREA)
Oncology (AREA)
Dermatology (AREA)
Molecular Biology (AREA)
Tropical Medicine & Parasitology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
Vascular Medicine (AREA)
Rheumatology (AREA)
Urology & Nephrology (AREA)
Pain & Pain Management (AREA)
Hematology (AREA)
AIDS & HIV (AREA)
Hospice & Palliative Care (AREA)
Transplantation (AREA)
Diabetes (AREA)
Psychiatry (AREA)
Ophthalmology & Optometry (AREA)

NO20034612A 2001-04-16 2003-10-15 3,4-di-substituerte syklobuten-1,2-dioner, farmasoytiske preparater som omfatter forbindelsene, samt anvendelse av forbindelsene for tilvirkning av medikamenter for behandling av kjemokinformidlede sykdommer NO330790B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US28402601P	2001-04-16	2001-04-16
PCT/US2002/012681 WO2002083624A1 (en)	2001-04-16	2002-04-15	3,4-di-substituted cyclobutene-1,2-diones as cxc-chemokine receptor ligands

Publications (3)

Publication Number	Publication Date
NO20034612D0 true NO20034612D0 (no)	2003-10-15
NO20034612L NO20034612L (no)	2003-12-08
NO330790B1 NO330790B1 (no)	2011-07-18

Family

ID=23088576

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
NO20034612A NO330790B1 (no)	2001-04-16	2003-10-15	3,4-di-substituerte syklobuten-1,2-dioner, farmasoytiske preparater som omfatter forbindelsene, samt anvendelse av forbindelsene for tilvirkning av medikamenter for behandling av kjemokinformidlede sykdommer
NO20110050A NO20110050L (no)	2001-04-16	2011-01-12	3,4-disubstituerte syklobuten-1,2-dioner som CXC-kjemokinreseptorligander

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
NO20110050A NO20110050L (no)	2001-04-16	2011-01-12	3,4-disubstituerte syklobuten-1,2-dioner som CXC-kjemokinreseptorligander

Country Status (30)

Country	Link
EP (2)	EP1818325B1 (no)
JP (3)	JP4499993B2 (no)
KR (2)	KR20100008794A (no)
CN (2)	CN1990457A (no)
AR (1)	AR035825A1 (no)
AT (2)	ATE365154T1 (no)
AU (3)	AU2002311841B2 (no)
BR (1)	BRPI0208957B8 (no)
CA (1)	CA2444031C (no)
CY (2)	CY1109908T1 (no)
CZ (1)	CZ20032831A3 (no)
DE (2)	DE60220778T2 (no)
DK (2)	DK1381590T3 (no)
EC (1)	ECSP034809A (no)
ES (2)	ES2340207T3 (no)
HU (1)	HUP0401783A3 (no)
IL (3)	IL158262A0 (no)
MX (1)	MXPA03009441A (no)
MY (2)	MY149050A (no)
NO (2)	NO330790B1 (no)
NZ (3)	NZ543869A (no)
PE (1)	PE20021084A1 (no)
PL (2)	PL207255B1 (no)
PT (2)	PT1381590E (no)
RU (1)	RU2344123C9 (no)
SI (2)	SI1381590T1 (no)
SK (1)	SK287598B6 (no)
TW (2)	TW200736196A (no)
WO (1)	WO2002083624A1 (no)
ZA (1)	ZA200307905B (no)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20040106794A1 (en)	2001-04-16	2004-06-03	Schering Corporation	3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
US7132445B2 (en)	2001-04-16	2006-11-07	Schering Corporation	3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
CA2462862A1 (en)	2001-10-12	2003-04-17	Schering Corporation	3,4-di-substituted maleimide compounds as cxc-chemokine receptor antagonists
US8246969B2 (en)	2001-11-16	2012-08-21	Skinmedica, Inc.	Compositions containing aromatic aldehydes and their use in treatments
US6878709B2 (en)	2002-01-04	2005-04-12	Schering Corporation	3,4-di-substituted pyridazinediones as CXC chemokine receptor antagonists
WO2003080053A1 (en) *	2002-03-18	2003-10-02	Schering Corporation	Combination treatments for chemokine-mediated diseases
GB0218326D0 (en) *	2002-08-07	2002-09-11	Glaxo Group Ltd	Compounds
ATE422203T1 (de)	2002-10-09	2009-02-15	Schering Corp	Thiadiazoldioxide und thiadiazoloxide als cxc- und cc-chemokinrezeptor liganden
GB0302094D0 (en)	2003-01-29	2003-02-26	Pharmagene Lab Ltd	EP4 receptor antagonists
EP1608369B1 (en)	2003-03-28	2013-06-26	Novartis Vaccines and Diagnostics, Inc.	Use of organic compounds for immunopotentiation
NZ543366A (en) *	2003-04-03	2008-11-28	Merck Patent Gmbh	Carbonyl compounds
ATE457307T1 (de)	2003-04-18	2010-02-15	Schering Corp	Synthese von 2-hydroxy-n,n-dimethyl-3-[[2-[1(r)- (5-methyl-2-furanyl)propyl amino -3,4-dioxo-1- cyclobuten-1-yl amino benzamid
BRPI0412259B1 (pt)	2003-07-22	2019-08-20	Astex Therapeutics Limited	Compostos de 1H-pirazol 3,4-dissubstituídos como moduladores de quinases dependentes de ciclina (CDK), seus usos, processo para a preparação dos mesmos e composição farmacêutica
GB0320983D0 (en) *	2003-09-08	2003-10-08	Biofocus Plc	Compound libraries
CA2538745A1 (en) *	2003-09-23	2005-03-31	Fermion Oy	Preparation of quetiapine
GB0324269D0 (en)	2003-10-16	2003-11-19	Pharmagene Lab Ltd	EP4 receptor antagonists
DE602004016211D1 (en)	2003-12-19	2008-10-09	Schering Corp	Thiadiazole als cxc- und cc-chemokinrezeptorliganden
JP4851943B2 (ja)	2003-12-22	2012-01-11	シェーリングコーポレイション	Ｃｘｃ−ケモカインレセプターリガンドおよびｃｃ−ケモカインレセプターリガンドとしてのイソチアゾールジオキシド
KR100883476B1 (ko) *	2004-01-30	2009-02-16	쉐링 코포레이션	Ｃｘｃ-케모킨 수용체 리간드의 결정성 다형체
CA2557301A1 (en) *	2004-02-27	2005-09-15	Schering Corporation	Cyclobutenedione groups-containing compounds as inhibitors of hepatitis c virus ns3 serine protease
WO2006023435A1 (en) *	2004-08-16	2006-03-02	The Procter & Gamble Company	2-(amino or substituted amino)-5, 6-substituted phenol compounds, dyeing compositions containing them, and use thereof
EP1634573A1 (en) *	2004-08-16	2006-03-15	The Procter and Gamble Company	2-(Amino or substituted Amino)-5,6-substituted Phenol compounds, dyeing compositions containing them, and use thereof
US7919496B2 (en)	2004-09-20	2011-04-05	Xenon Pharmaceuticals Inc.	Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-CoA desaturase enzymes
CA2580844A1 (en)	2004-09-20	2006-03-30	Xenon Pharmaceuticals Inc.	Heterocyclic derivatives and their use as mediators of stearoyl-coa desaturase
WO2006034441A1 (en)	2004-09-20	2006-03-30	Xenon Pharmaceuticals Inc.	Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
JP4958785B2 (ja)	2004-09-20	2012-06-20	ゼノン・ファーマシューティカルズ・インコーポレイテッド	複素環誘導体およびステアロイル−ＣｏＡデサチュラーゼインヒビターとしてのそれらの使用
CN101084211A (zh)	2004-09-20	2007-12-05	泽农医药公司	杂环衍生物及其作为治疗剂的用途
US7767677B2 (en)	2004-09-20	2010-08-03	Xenon Pharmaceuticals Inc.	Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
AR051094A1 (es)	2004-09-20	2006-12-20	Xenon Pharmaceuticals Inc	Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
EP2096107A1 (en)	2004-12-23	2009-09-02	GPC Biotech AG	Derivatives of squaric acid with anti-proliferative activity
US8404718B2 (en)	2005-01-21	2013-03-26	Astex Therapeutics Limited	Combinations of pyrazole kinase inhibitors
AR054425A1 (es)	2005-01-21	2007-06-27	Astex Therapeutics Ltd	Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
EP2540296A1 (en)	2005-06-03	2013-01-02	Xenon Pharmaceuticals Inc.	Arminothiazole derivatives as human stearoyl-coa desaturase inhibitors
CN101253165A (zh)	2005-06-29	2008-08-27	先灵公司	作为cxc－化学活素受体配体的二取代的二唑
WO2007005403A1 (en)	2005-06-29	2007-01-11	Schering Corporation	5,6-di-substituted oxadiazolopyrazines and thiadiazolopyrazines as cxc-chemokine receptor ligands
DE102005035742A1 (de) *	2005-07-29	2007-02-01	Merck Patent Gmbh	Quadratsäurederivate II
PT1951663T (pt) *	2005-11-24	2016-10-03	Dompé Farm S P A	¿derivados (r)-arilalquilamino e composições farmacêuticas que os contêm
CN101448778A (zh) *	2006-05-26	2009-06-03	艾博特公司	Polo样激酶的抑制剂
TWI351399B (en) *	2006-06-12	2011-11-01	Schering Corp	Pharmaceutical formulations and compositions of a
PE20080553A1 (es) *	2006-07-07	2008-05-16	Schering Corp	Ciclobuten-1,2-dionas 3,4-di-sustituidas como ligandos de receptores de quimiocinas cxc
US8450348B2 (en)	2007-02-21	2013-05-28	Forma Tm, Llc	Derivatives of squaric acid with anti-proliferative activity
MX2009013276A (es) *	2007-06-06	2010-01-25	Novartis Ag	Compuestos anti-inflamatorios de ciclobutenodiona sustituida.
US8519168B2 (en) *	2007-07-03	2013-08-27	Merck Sharp & Dohme Corp.	Process and intermediates for the synthesis of 1,2-substituted 3,4-dioxo-1-cyclobutene compounds
US9006426B2 (en) *	2008-06-24	2015-04-14	Topotarget A/S	Squaric acid derivatives as inhibitors of the nicotinamide
UA103198C2 (en)	2008-08-04	2013-09-25	Новартис Аг	Squaramide derivatives as cxcr2 antagonists
WO2010063802A1 (en) *	2008-12-05	2010-06-10	Novartis Ag	3, 4-di-substituted cyclobutene- 1, 2 -diones as cxcr2 receptor antagonists
US8293738B2 (en)	2010-05-12	2012-10-23	Abbott Laboratories	Indazole inhibitors of kinase
FR2961695B1 (fr) *	2010-06-29	2012-07-06	Galderma Res & Dev	Utilisation de composes dans le traitement ou la prevention de troubles cutanes
PH12013501427B1 (en)	2011-01-07	2019-02-13	Allergan Inc	Melanin modification compositions and methods of use
CN103842330B (zh)	2011-09-02	2016-10-19	诺华股份有限公司	抗炎的取代的环丁烯二酮化合物的胆碱盐
FR2981936B1 (fr)	2011-10-28	2013-12-20	Galderma Res & Dev	Nouveaux composes di-substitues de la diamino-3,4-cyclobutene-3-dione-1,2 utiles dans le traitement de pathologies mediees par des chimiokines.
FR2981934B1 (fr)	2011-10-28	2013-12-20	Galderma Res & Dev	Nouveaux composes di-substitues de la diamino-3,4-cyclobutene-3-dione-1,2 utiles dans le traitement de pathologies mediees par des chimiokines.
FR2981935B1 (fr)	2011-10-28	2015-08-07	Galderma Res & Dev	Nouveaux composes di-substitues de la diamino-3,4-cyclobutene-3-dione-1,2 utiles dans le traitement de pathologies mediees par des chimiokines.
CN103242210B (zh) *	2012-02-09	2014-09-24	北京艾百诺科技有限公司	含有取代方酸的乙酸妙林酯及其应用
CN104302640A (zh)	2012-03-16	2015-01-21	埃克希金医药品有限公司	3,5-二氨基吡唑激酶抑制剂
US8889730B2 (en)	2012-04-10	2014-11-18	Pfizer Inc.	Indole and indazole compounds that activate AMPK
CN103382192A (zh) *	2012-05-04	2013-11-06	同创医药(苏州)有限公司	N-单取代哌嗪衍生物的制备
CA2905242C (en)	2013-03-15	2016-11-29	Pfizer Inc.	Indole compounds that activate ampk
CN103214327A (zh) *	2013-03-22	2013-07-24	郑州泰基鸿诺药物科技有限公司	一种芳香环或芳杂环三氟甲基酮化合物及其制备方法
US10046002B2 (en)	2013-08-02	2018-08-14	Syntrix Biosystems Inc.	Method for treating cancer using chemokine antagonists
US10561676B2 (en) *	2013-08-02	2020-02-18	Syntrix Biosystems Inc.	Method for treating cancer using dual antagonists of CXCR1 and CXCR2
NZ631142A (en)	2013-09-18	2016-03-31	Axikin Pharmaceuticals Inc	Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
HUE049801T2 (hu)	2014-12-23	2020-10-28	Sma Therapeutics Inc	3,5-diaminopirazol kináz inhibitorok
FR3030515B1 (fr)	2014-12-23	2017-01-20	Galderma Res & Dev	Nouveaux composes antagonistes des recepteurs cxcr1 et cxcr2 aux chimiokines, et leur utilisation dans le traitement de pathologies mediees par des chimiokines
TWI734715B (zh)	2015-11-19	2021-08-01	美商卡默森屈有限公司	趨化因子受體調節劑
TWI724056B (zh) *	2015-11-19	2021-04-11	美商卡默森屈有限公司	Ｃｘｃｒ２抑制劑
WO2018073248A1 (en)	2016-10-17	2018-04-26	Icm (Institut Du Cerveau Et De La Moelle Épinière)	Prognosis of demyelinating diseases patients and treatment thereof
EP3668832A1 (en) *	2017-08-14	2020-06-24	Allergan, Inc.	3,4-disubstituted 3-cyclobutene-1,2-diones and use thereof
WO2019067332A1 (en)	2017-09-27	2019-04-04	Merck Sharp & Dohme Corp.	COMPOSITIONS AND METHODS FOR TREATING CANCER THROUGH A COMBINATION OF PROGRAMMED DEATH ANTIBODY ANTIBODIES (PD-1) AND A CXCR2 ANTAGONIST
AU2019205786B2 (en)	2018-01-08	2023-12-14	Chemocentryx, Inc.	Methods of treating generalized pustular psoriasis with an antagonist of CCR6 or CXCR2
SG11202101827RA (en)	2018-09-21	2021-04-29	Pfizer	N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamides useful as ccr6 inhibitors
CN110041309B (zh) *	2019-04-04	2022-01-28	广东工业大学	一种2-羧基哌嗪连接的他克林-8-氨基(羟基)喹啉衍生物及制备与应用
BR112022006226A2 (pt) *	2019-10-07	2022-06-28	De Shaw Res Llc	Compostos heterocíclicos de arilmetileno como bloqueadores de canal do agitador de potássio kv1,3
KR102710925B1 (ko) *	2021-06-01	2024-09-27	부산대학교 산학협력단	신규 스퀘어아마이드 유도체 및 이의 용도
CN118339161B (zh) *	2021-12-10	2025-12-09	正大天晴药业集团股份有限公司	一种异噻唑并[5,4-d]嘧啶类IRAK4抑制剂的制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH0692915A (ja) *	1992-07-28	1994-04-05	Sumitomo Metal Ind Ltd	１，２−ジアミノシクロブテン−３，４−ジオン誘導体及びその用途
GB9312210D0 (en) *	1993-06-14	1993-07-28	Smithkline Beecham Plc	Chemical compounds
GB9316111D0 (en) *	1993-08-04	1993-09-22	Pfizer Ltd	Benzopyrans
US5354763A (en) *	1993-11-17	1994-10-11	American Home Products Corporation	Substituted N-heteroaryl and N-aryl-1,2-diaminocyclobutene-3,4-diones
US5466712A (en) *	1994-11-04	1995-11-14	American Home Products Corporation	Substituted n-aryl-1,2-diaminocyclobutene-3,4-diones
WO1996015103A1 (en) *	1994-11-16	1996-05-23	American Home Products Corporation	Diaminocyclobutene-3,4-diones
BR9709938A (pt) *	1996-06-27	1999-08-10	Smithkline Beecham Corp	Antagonistas dos receptores de il-8
US5840764A (en) *	1997-01-30	1998-11-24	American Home Products Corporation	Substituted hydroxy-anilino derivatives of cyclobutene-3,4-diones
AU6250298A (en) *	1997-01-30	1998-08-25	American Home Products Corporation	Substituted hydroxy-anilino derivatives of cyclobutene-3,4-diones
US6211220B1 (en) *	1998-11-23	2001-04-03	Cell Pathways, Inc.	Method for treating neoplasia with amino or pyridylamino cyclobutene derivatives
CA2351464A1 (en) *	1998-12-14	2000-06-22	Joan E. Sabalski	3,4-diamino-3-cyclobutene-1,2-dione derivatives which inhibit leukocyte adhesion mediated by vla-4
CA2355161A1 (en) *	1998-12-16	2000-06-22	Bayer Aktiengesellschaft	Biphenyl and biphenyl-analogous compounds as integrin antagonists
US6518283B1 (en) *	1999-05-28	2003-02-11	Celltech R&D Limited	Squaric acid derivatives
AR033803A1 (es) *	2000-03-01	2004-01-07	Smithkline Beecham Corp	Compuestos de dianilino escuarano, composiciones farmaceuticas que los comprenden, y el uso de los mismos en la fabricacion de medicamentos para tratar enfermedades mediadas por quimioquinas
IL152775A0 (en) *	2000-05-30	2003-06-24	Smithkline Beecham Corp	Il-8 receptor antagonists
WO2002057230A1 (en) *	2001-01-16	2002-07-25	Smithkline Beecham Corporation	Il-8 receptor antagonists
JP2005507366A (ja) *	2001-03-30	2005-03-17	スミスクライン・ビーチャム・コーポレイション	フェノール含有化合物の合成方法
WO2003080053A1 (en) *	2002-03-18	2003-10-02	Schering Corporation	Combination treatments for chemokine-mediated diseases

2002
- 2002-04-15 RU RU2003133448/04A patent/RU2344123C9/ru not_active IP Right Cessation
- 2002-04-15 BR BRPI0208957 patent/BRPI0208957B8/pt not_active IP Right Cessation
- 2002-04-15 NZ NZ543869A patent/NZ543869A/en not_active IP Right Cessation
- 2002-04-15 KR KR1020097026265A patent/KR20100008794A/ko not_active Ceased
- 2002-04-15 ES ES07010711T patent/ES2340207T3/es not_active Expired - Lifetime
- 2002-04-15 NZ NZ560453A patent/NZ560453A/en unknown
- 2002-04-15 AT AT02739172T patent/ATE365154T1/de active
- 2002-04-15 MX MXPA03009441A patent/MXPA03009441A/es active IP Right Grant
- 2002-04-15 CZ CZ20032831A patent/CZ20032831A3/cs unknown
- 2002-04-15 ES ES02739172T patent/ES2287284T3/es not_active Expired - Lifetime
- 2002-04-15 AU AU2002311841A patent/AU2002311841B2/en not_active Expired
- 2002-04-15 CN CNA2006101374093A patent/CN1990457A/zh active Pending
- 2002-04-15 PL PL367129A patent/PL207255B1/pl unknown
- 2002-04-15 AR ARP020101371A patent/AR035825A1/es not_active Application Discontinuation
- 2002-04-15 PT PT02739172T patent/PT1381590E/pt unknown
- 2002-04-15 EP EP07010711A patent/EP1818325B1/en not_active Expired - Lifetime
- 2002-04-15 DE DE60220778T patent/DE60220778T2/de not_active Expired - Lifetime
- 2002-04-15 DK DK02739172T patent/DK1381590T3/da active
- 2002-04-15 KR KR1020037013527A patent/KR100952531B1/ko not_active Expired - Fee Related
- 2002-04-15 SK SK1288-2003A patent/SK287598B6/sk not_active IP Right Cessation
- 2002-04-15 WO PCT/US2002/012681 patent/WO2002083624A1/en not_active Ceased
- 2002-04-15 MY MYPI20070922A patent/MY149050A/en unknown
- 2002-04-15 HU HU0401783A patent/HUP0401783A3/hu unknown
- 2002-04-15 DE DE60235507T patent/DE60235507D1/de not_active Expired - Lifetime
- 2002-04-15 PT PT07010711T patent/PT1818325E/pt unknown
- 2002-04-15 SI SI200230572T patent/SI1381590T1/sl unknown
- 2002-04-15 IL IL15826202A patent/IL158262A0/xx unknown
- 2002-04-15 EP EP02739172A patent/EP1381590B1/en not_active Expired - Lifetime
- 2002-04-15 JP JP2002581381A patent/JP4499993B2/ja not_active Expired - Lifetime
- 2002-04-15 CA CA2444031A patent/CA2444031C/en not_active Expired - Lifetime
- 2002-04-15 MY MYPI20021372A patent/MY138202A/en unknown
- 2002-04-15 AT AT07010711T patent/ATE458715T1/de active
- 2002-04-15 PL PL390082A patent/PL208928B1/pl unknown
- 2002-04-15 NZ NZ529551A patent/NZ529551A/en not_active IP Right Cessation
- 2002-04-15 SI SI200230898T patent/SI1818325T1/sl unknown
- 2002-04-15 CN CNB028119797A patent/CN1289471C/zh not_active Expired - Fee Related
- 2002-04-15 DK DK07010711.5T patent/DK1818325T3/da active
- 2002-04-16 TW TW096102669A patent/TW200736196A/zh unknown
- 2002-04-16 TW TW091107670A patent/TWI316930B/zh active
- 2002-04-16 PE PE2002000318A patent/PE20021084A1/es not_active Application Discontinuation
2003
- 2003-10-02 IL IL158262A patent/IL158262A/en not_active IP Right Cessation
- 2003-10-09 ZA ZA2003/07905A patent/ZA200307905B/en unknown
- 2003-10-15 NO NO20034612A patent/NO330790B1/no not_active IP Right Cessation
- 2003-10-16 EC EC2003004809A patent/ECSP034809A/es unknown
2006
- 2006-08-24 AU AU2006203679A patent/AU2006203679A1/en not_active Abandoned
2007
- 2007-08-07 CY CY20071101059T patent/CY1109908T1/el unknown
2009
- 2009-05-20 JP JP2009122594A patent/JP2009179641A/ja active Pending
- 2009-10-25 IL IL201754A patent/IL201754A0/en unknown
- 2009-12-08 JP JP2009278869A patent/JP5294418B2/ja not_active Expired - Lifetime
2010
- 2010-04-29 CY CY20101100380T patent/CY1109989T1/el unknown
- 2010-08-20 AU AU2010212484A patent/AU2010212484B2/en not_active Expired
2011
- 2011-01-12 NO NO20110050A patent/NO20110050L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
JP2004532846A (ja)	2004-10-28
KR20030092074A (ko)	2003-12-03
CN1289471C (zh)	2006-12-13
JP4499993B2 (ja)	2010-07-14
AU2010212484A1 (en)	2010-09-09
JP5294418B2 (ja)	2013-09-18
PL208928B1 (pl)	2011-06-30
CN1990457A (zh)	2007-07-04
HUP0401783A2 (hu)	2005-01-28
MY138202A (en)	2009-05-29
ZA200307905B (en)	2005-03-30
PT1818325E (pt)	2010-05-12
DE60235507D1 (de)	2010-04-08
CN1516687A (zh)	2004-07-28
NO20110050L (no)	2003-12-08
DK1381590T3 (da)	2007-10-22
ATE458715T1 (de)	2010-03-15
IL158262A0 (en)	2004-05-12
SI1818325T1 (sl)	2010-06-30
AU2006203679A1 (en)	2006-09-14
EP1818325A2 (en)	2007-08-15
NZ560453A (en)	2009-03-31
WO2002083624A1 (en)	2002-10-24
KR20100008794A (ko)	2010-01-26
PT1381590E (pt)	2007-08-06
CY1109908T1 (el)	2014-09-10
AU2002311841B2 (en)	2006-09-14
CA2444031C (en)	2012-02-21
ATE365154T1 (de)	2007-07-15
DE60220778T2 (de)	2008-03-06
AR035825A1 (es)	2004-07-14
PE20021084A1 (es)	2002-12-20
BR0208957A (pt)	2004-06-22
ES2287284T3 (es)	2007-12-16
CA2444031A1 (en)	2002-10-24
DK1818325T3 (da)	2010-05-31
EP1381590A1 (en)	2004-01-21
TWI316930B (en)	2009-11-11
KR100952531B1 (ko)	2010-04-12
ECSP034809A (es)	2004-02-26
ES2340207T3 (es)	2010-05-31
RU2344123C9 (ru)	2009-05-20
PL207255B1 (pl)	2010-11-30
IL158262A (en)	2012-05-31
NZ543869A (en)	2007-09-28
RU2003133448A (ru)	2005-06-10
DE60220778D1 (en)	2007-08-02
HK1107818A1 (en)	2008-04-18
MY149050A (en)	2013-07-15
EP1818325A3 (en)	2008-02-13
BRPI0208957B8 (pt)	2021-05-25
IL201754A0 (en)	2010-06-16
PL367129A1 (en)	2005-02-21
CZ20032831A3 (cs)	2004-03-17
JP2009179641A (ja)	2009-08-13
HK1057538A1 (en)	2004-04-08
AU2010212484B2 (en)	2012-04-12
SI1381590T1 (sl)	2007-10-31
NO20034612L (no)	2003-12-08
SK287598B6 (sk)	2011-03-04
RU2344123C2 (ru)	2009-01-20
JP2010053151A (ja)	2010-03-11
SK12882003A3 (sk)	2004-06-08
NO330790B1 (no)	2011-07-18
EP1381590B1 (en)	2007-06-20
BRPI0208957B1 (pt)	2018-10-09
TW200736196A (en)	2007-10-01
EP1818325B1 (en)	2010-02-24
NZ529551A (en)	2006-02-24
CY1109989T1 (el)	2014-09-10
HUP0401783A3 (en)	2005-06-28
MXPA03009441A (es)	2004-02-12

Publication	Publication Date	Title
NO20034612D0 (no)	2003-10-15	3,4-di-substituerte syklobuten-1,2-dioner som CXC-kjemokine reseptorligander
MXPA03006950A (es)	2003-11-18	Ciclobuteno-1,2-dionas 3,4-disustituidas como antagonistas de receptor de quimiocina cxc.
ITTO20010940A0 (it)	2001-10-04	,,sedia,,
ATE380194T1 (de)	2007-12-15	6.alpha.,9.alpha.-difluoro-17.alpha.-(2-
AU2003207460A1 (en)	2003-07-24	3,4-di-substituted pyridazinediones as cxc chemokine receptor antagonists
DE60210598D1 (de)	2006-05-24	3,7-DIAZABICYCLOc3.3.1Ü-FORMULIERUNGEN ALS ANTIARRHYTHMIKA
ITMI20000945A0 (it)	2000-04-28	Struttura di sella, particolarmente studiata per cicli
ITTO20020004A0 (it)	2002-01-03	Struttura di sella di motociclo.
DE60213084D1 (de)	2006-08-24	3,7-DIAZABICYCLOc3.3.1Ü-FORMULIERUNGEN ALS ANTIARRHYTHMIKA
NO20044413L (no)	2004-10-18	1,2-Dihydropyrazol-3-oner som cytokinmediatorer
HK1057884A (en)	2004-04-23	3,4-di-substituted cyclobutene-1, 2-diones as cxc chemokine receptor antagonists
DE50214487D1 (de)	2010-07-22	Substituierte 1,5-diaminopentan-3-ol-verbindungen
Srinivasan	2001	Bhagavatikitranamruta-Bindhu-CS Srinivasan
BR8101523Y1 (pt)	2009-08-11	disposição construtiva aplicada à cadeira.
HK1064672A (en)	2005-02-04	3,4-di-substituted pyridazinediones as cxc chemokine receptor antagonists
ES1048499Y (es)	2001-12-16	Persiana compacta.
DOP2001000275A (es)	2002-05-30	Inhibidores de metaloproteinasa del tipo pirmidin-2,4,6-triona.
IT1318986B1 (it)	2003-09-19	Procedimento per la preparazione di (s)-n-terbutil-1,2,3,4-tetraidroisochinolin-3-carbossiammide.
ES1049547Y (es)	2002-04-16	Estructura de soporte mejorada.
ES1049925Y (es)	2002-06-01	Almohadilla tatuadora.
ES1051328Y (es)	2002-11-01	Bañera compacta.
ES1049882Y (es)	2002-06-01	Asiento polivalente.
ES1048590Y (es)	2001-12-16	Soporte escurre tapas antisalpicaduras domestico.
ES1049573Y (es)	2002-04-16	Tarima de soporte perfeccionada.
ITSA20010003V0 (it)	2001-04-11	"multifase 2001".

Legal Events

Date	Code	Title	Description
2011-02-14	FC2A	Withdrawal, rejection or dismissal of laid open patent application
2011-04-26	FC2A	Withdrawal, rejection or dismissal of laid open patent application
2012-09-24	CHAD	Change of the owner's name or address (par. 44 patent law, par. patentforskriften)	Owner name: MERCK SHARP AND DOHME CORP Free format text: NEW ADDRESS: 126 EAST LINCOLN AVENUE, US-NJ07065 RAHWAY, US
2015-11-23	MM1K	Lapsed by not paying the annual fees